132 related articles for article (PubMed ID: 22958125)
1. Differential expression of PHLDA1 (TDAG51) in basal cell carcinoma and trichoepithelioma.
Yeh I; McCalmont TH; LeBoit PE
Br J Dermatol; 2012 Nov; 167(5):1106-10. PubMed ID: 22958125
[TBL] [Abstract][Full Text] [Related]
2. Follicular stem cell marker PHLDA1 (TDAG51) is superior to cytokeratin-20 in differentiating between trichoepithelioma and basal cell carcinoma in small biopsy specimens.
Sellheyer K; Nelson P
J Cutan Pathol; 2011 Jul; 38(7):542-50. PubMed ID: 21352265
[TBL] [Abstract][Full Text] [Related]
3. PHLDA1 (TDAG51) is a follicular stem cell marker and differentiates between morphoeic basal cell carcinoma and desmoplastic trichoepithelioma.
Sellheyer K; Krahl D
Br J Dermatol; 2011 Jan; 164(1):141-7. PubMed ID: 20846311
[TBL] [Abstract][Full Text] [Related]
4. The immunohistochemical differential diagnosis of microcystic adnexal carcinoma, desmoplastic trichoepithelioma and morpheaform basal cell carcinoma using BerEP4 and stem cell markers.
Sellheyer K; Nelson P; Kutzner H; Patel RM
J Cutan Pathol; 2013 Apr; 40(4):363-70. PubMed ID: 23398472
[TBL] [Abstract][Full Text] [Related]
5. Fibroepithelioma of Pinkus is a true basal cell carcinoma developing in association with a newly identified tumour-specific type of epidermal hyperplasia.
Sellheyer K; Nelson P; Kutzner H
Br J Dermatol; 2012 Jan; 166(1):88-97. PubMed ID: 21910710
[TBL] [Abstract][Full Text] [Related]
6. Basaloid tumors in nevus sebaceus revisited: the follicular stem cell marker PHLDA1 (TDAG51) indicates that most are basal cell carcinomas and not trichoblastomas.
Sellheyer K; Cribier B; Nelson P; Kutzner H; Rütten A
J Cutan Pathol; 2013 May; 40(5):455-62. PubMed ID: 23489134
[TBL] [Abstract][Full Text] [Related]
7. PHLDA1, a follicular stem cell marker, differentiates clear-cell/granular-cell trichoblastoma and clear-cell/granular cell basal cell carcinoma: a case-control study, with first description of granular-cell trichoblastoma.
Battistella M; Peltre B; Cribier B
Am J Dermatopathol; 2014 Aug; 36(8):643-50. PubMed ID: 23719479
[TBL] [Abstract][Full Text] [Related]
8. Expression of p75 neurotrophin receptor in desmoplastic trichoepithelioma, infiltrative basal cell carcinoma, and microcystic adnexal carcinoma.
Jedrych J; McNiff JM
Am J Dermatopathol; 2013 May; 35(3):308-15. PubMed ID: 23598854
[TBL] [Abstract][Full Text] [Related]
9. Comparative analysis of cytokeratin 15, TDAG51, cytokeratin 20 and androgen receptor in sclerosing adnexal neoplasms and variants of basal cell carcinoma.
Evangelista MT; North JP
J Cutan Pathol; 2015 Nov; 42(11):824-31. PubMed ID: 26016446
[TBL] [Abstract][Full Text] [Related]
10. Cytokeratin 20 expression in basaloid follicular hamartoma and infundibulocystic basal cell carcinoma.
Honarpisheh H; Glusac EJ; Ko CJ
J Cutan Pathol; 2014 Dec; 41(12):916-21. PubMed ID: 25353070
[TBL] [Abstract][Full Text] [Related]
11. Immunohistologic differential diagnosis of basal cell carcinoma, squamous cell carcinoma, and trichoepithelioma in small cutaneous biopsy specimens.
Swanson PE; Fitzpatrick MM; Ritter JH; Glusac EJ; Wick MR
J Cutan Pathol; 1998 Mar; 25(3):153-9. PubMed ID: 9550314
[TBL] [Abstract][Full Text] [Related]
12. Immunolabeling pattern of podoplanin (d2-40) may distinguish basal cell carcinomas from trichoepitheliomas: a clinicopathologic and immunohistochemical study of 49 cases.
Plaza JA; Ortega PF; Bengana C; Stockman DL; Suster S
Am J Dermatopathol; 2010 Oct; 32(7):683-7. PubMed ID: 20559122
[TBL] [Abstract][Full Text] [Related]
13. Bcl-2 and CD10 expression in the differential diagnosis of trichoblastoma, basal cell carcinoma, and basal cell carcinoma with follicular differentiation.
Córdoba A; Guerrero D; Larrinaga B; Iglesias ME; Arrechea MA; Yanguas JI
Int J Dermatol; 2009 Jul; 48(7):713-7. PubMed ID: 19570076
[TBL] [Abstract][Full Text] [Related]
14. Increased immunoreactivity of membrane type-1 matrix metalloproteinase (MT1-MMP) and β-catenin in high-risk basal cell carcinoma.
Oh ST; Kim HS; Yoo NJ; Lee WS; Cho BK; Reichrath J
Br J Dermatol; 2011 Dec; 165(6):1197-204. PubMed ID: 21729023
[TBL] [Abstract][Full Text] [Related]
15. Monoclonal antibody Ber-EP4 reliably discriminates between microcystic adnexal carcinoma and basal cell carcinoma.
Krahl D; Sellheyer K
J Cutan Pathol; 2007 Oct; 34(10):782-7. PubMed ID: 17880584
[TBL] [Abstract][Full Text] [Related]
16. Characteristic Ber-EP4 and EMA expression in sebaceoma is immunohistochemically distinct from basal cell carcinoma.
Fan YS; Carr RA; Sanders DS; Smith AP; Lazar AJ; Calonje E
Histopathology; 2007 Jul; 51(1):80-6. PubMed ID: 17593083
[TBL] [Abstract][Full Text] [Related]
17. Differentiation between basal cell carcinoma and trichoepithelioma by immunohistochemical staining of the androgen receptor: an overview.
Arits AH; Van Marion AM; Lohman BG; Thissen MR; Steijlen PM; Nelemans PJ; Kelleners-Smeets NW
Eur J Dermatol; 2011; 21(6):870-3. PubMed ID: 21865121
[TBL] [Abstract][Full Text] [Related]
18. Proliferative characterization of basal-cell carcinoma and trichoepithelioma in small biopsy specimens.
Lum CA; Binder SW
J Cutan Pathol; 2004 Sep; 31(8):550-4. PubMed ID: 15268710
[TBL] [Abstract][Full Text] [Related]
19. Does the peritumoral stroma of basal cell carcinoma recapitulate the follicular connective tissue sheath?
Sellheyer K; Krahl D
J Cutan Pathol; 2011 Jul; 38(7):551-9. PubMed ID: 21366662
[TBL] [Abstract][Full Text] [Related]
20. Superficial radiotherapy for patients with basal cell carcinoma: recurrence rates, histologic subtypes, and expression of p53 and Bcl-2.
Zagrodnik B; Kempf W; Seifert B; Müller B; Burg G; Urosevic M; Dummer R
Cancer; 2003 Dec; 98(12):2708-14. PubMed ID: 14669293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
